Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

MDR-RA Defining Clinical and Molecular Phenotypes of Multi-Drug Resistance in difficult to treat Rheumatoid Arthritis

Coordinator
Universita Humanitas, Italy
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€7.4m
Total cost
—
Partners
25 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101155807

What the project is doing

In the project's own words, from its summary on CORDIS.

Rheumatoid Arthritis (RA) is the most common, chronic, inflammatory joint disease with a prevalence of about 1% of the adult population (22M patients worldwide and 7M in EU) and estimated to be responsible for 10,000 disability adjusted life years (DALY's) costing EU society €55B annually. Despite aggressive therapy, about a third of patients have to give up work within 5 years of disease onset mainly due to lack of response to multiple disease modifying anti-rheumatic drugs (DMARDs), multi-drug resistance (MDR).

Thus, the main objective of this proposal is to define the clinical and molecular phenotypes leading to MDR in RA patients to prevent when possible or, when not possible, optimise the management of these patients. MDR-RA is highly relevant to the program, as these patients are often disabled, unable to work and paying a high personal and societal burden. Moreover, MDR-RA is under-researched and the underlying pathobiological mechanisms for resistance remain unknown, while as we have no predictors of therapeutic response to any of currently available drugs, inevitably treatment is based on trial-and-error.

MDR-RA has the ambition of transforming care for these patients and deliver significant advances beyond the state-of-the-art methodologies, as for the first time, molecular pathology will be integrated into clinical, psychosocial, pain perception and imaging profiling in existing clinical cohorts to develop truly holistic predictive models for future clinical use (iCare-RA). The transformative potential of iCare-RA will be tested in a prospective randomised trial in comparison with routine standard of care, while its future implementation potential will be assessed through an early economic modelling.

Finally, a strong management and dissemination strategy will facilitate further advancing science in the field, beyond the duration of the project, and future adoption by patients, specialist professional bodies, policy makers and regulatory authorities.

Who is involved

OrganisationCityCountryRole
Universita HumanitasPieve EmanueleItalyCoordinator
Eutema Research Services GmbHWienAustriaParticipant
Medizinische Universitaet WienWienAustriaParticipant
Cliniques Universitaires Saint-Luc ASBLBruxelles / BrusselBelgiumParticipant
Aardex Group SASionSwitzerlandAssociatedpartner
European Alliance of Associations for RheumatologyZurichSwitzerlandAssociatedpartner
HOCH Health OstschweizSt. GallenSwitzerlandAssociatedpartner
Universitat BaselBaselSwitzerlandAssociatedpartner
Universitat ZurichZurichSwitzerlandAssociatedpartner
Universitatsklinikum ErlangenErlangenGermanyParticipant
Region SyddanmarkVejleDenmarkParticipant
Fundacion Para La Investigacion Biomedica De CordobaCordobaSpainThird party
Instituto De Salud Musculoesqueletica SLMadridSpainParticipant
Servicio Andaluz De SaludSevillaSpainParticipant
Humanitas Mirasole SpARozzano (Mi)ItalyThird party
Pluribus One SRLCagliariItalyParticipant
Universita Cattolica Del Sacro CuoreMilanoItalyParticipant
Universita Degli Studi Di VeronaVeronaItalyParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Diakonhjemmet Sykehus ASOsloNorwayParticipant
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant
Karolinska InstitutetStockholmSwedenParticipant
Region StockholmStockholmSwedenParticipant
Queen Mary University of LondonLondonUnited KingdomParticipant
The University of ManchesterManchesterUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI